Form 4: Actuate Therapeutics Director, Dan Zabrowski, Reports Acquisition of 15,000 Stock Options

Director Dan Zabrowski reports acquiring 15,000 stock options in Actuate Therapeutics following the company's initial public offering.

Summary

• Dan Zabrowski, a director of Actuate Therapeutics, reported the acquisition of 15,000 non-qualified stock options on August 12, 2024.
• These options were granted upon the effectiveness of the registration statement for the issuer's initial public offering.
• The exercise price of the options is $8.
• The options vest in full on the first anniversary of the grant date, August 12, 2025, and expire on August 12, 2034.
• Following the transaction, Zabrowski directly owns 15,000 derivative securities.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral to positive as it indicates alignment of interests between management and shareholders. The IPO itself is a positive event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions following Actuate Therapeutics' initial public offering. It is common for directors and officers to receive stock options as part of their compensation packages, especially after an IPO.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The vesting schedule of one year is fairly typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies often include those in similar stages of development and market capitalization, such as early-stage biotech firms listed on NASDAQ or other major exchanges.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's growth and potential.

Key Dates